We are live on
!
Find out more
Squarepoint Portfolio holdings
AUM
$85.1B
1-Year Est. Return
20.93%
This Fund
S&P 500
This Quarter
Est. Return
+7.16%
1 Year Est. Return
+20.93%
3 Year Est. Return
+51.38%
5 Year Est. Return
+34.63%
10 Year Est. Return
+146.23%
AUM
$7.42B
AUM Growth
+$1.24B
(+20%)
Cap. Flow
+$985M
Cap. Flow
% of AUM
13.27%
Top 10 Holdings %
Top 10 Hldgs %
10.68%
Holding
3,037
New
854
Increased
791
Reduced
777
Closed
600
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$49.3M |
| 2 |
Intuit
INTU
|
+$48.7M |
| 3 |
Costco
COST
|
+$47.9M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$47.4M |
| 5 |
Vanguard Real Estate ETF
VNQ
|
+$45.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$41M |
| 2 |
Dollar General
DG
|
+$39M |
| 3 |
Biogen
BIIB
|
+$36.8M |
| 4 |
iShares US Real Estate ETF
IYR
|
+$29.8M |
| 5 |
Waste Management
WM
|
+$29.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.19% |
| 2 | Consumer Discretionary | 16.12% |
| 3 | Healthcare | 11.21% |
| 4 | Financials | 10.17% |
| 5 | Industrials | 9.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
REX American Resources
REX
$1.46B
| $229K | ﹤0.01% |
+20,952
| New | +$238K |
|
2002
Cogent Biosciences
COGT
$6.79B
| $228K | ﹤0.01% |
+24,339
| New | +$254K |
|
2003
Collegium Pharmaceutical
COLL
$1.14B
| $228K | ﹤0.01% |
10,944
-7,317
| -40% | -$132K |
|
2004
Agilysys
AGYS
$2.78B
| $227K | ﹤0.01% |
+9,408
| New | +$210K |
|
2005
Asure Software
ASUR
$220M
| $226K | ﹤0.01% |
29,871
-19,828
| -40% | -$135K |
|
2006
Mueller Water Products
MWA
$3.92B
| $226K | ﹤0.01% |
+21,789
| New | +$227K |
|
|
NPKI
2007
NPK International
NPKI
$1.21B
| $226K | ﹤0.01% |
214,807
+174,526
| +433% | +$321K |
|
|
GBL
2008
DELISTED
GAMCO Investors, Inc.
GBL
| $226K | ﹤0.01% |
+19,495
| New | +$245K |
|
|
CLCT
2009
DELISTED
Collectors Universe
CLCT
| $226K | ﹤0.01% |
+4,563
| New | +$196K |
|
2010
Aprea Therapeutics
APRE
$7.83M
| $225K | ﹤0.01% |
+469
| New | +$262K |
|
|
KLR
2011
DELISTED
Kaleyra, Inc.
KLR
| $225K | ﹤0.01% |
+8,472
| New | +$176K |
|
2012
Asbury Automotive
ABG
$4.19B
| $223K | ﹤0.01% |
2,290
-10,210
| -82% | -$1.03M |
|
2013
RLJ Lodging Trust
RLJ
$1.87B
| $223K | ﹤0.01% |
+25,752
| New | +$231K |
|
2014
Allogene Therapeutics
ALLO
$601M
| $222K | ﹤0.01% |
+5,900
| New | +$222K |
|
2015
Immatics
IMTX
$1.24B
| $222K | ﹤0.01% |
+20,938
| New | +$221K |
|
2016
Rhythm Pharmaceuticals
RYTM
$7B
| $222K | ﹤0.01% |
+10,239
| New | +$235K |
|
2017
APi Group
APG
$17.1B
| $221K | ﹤0.01% |
+23,274
| New | +$214K |
|
2018
Silgan Holdings
SLGN
$4.91B
| $221K | ﹤0.01% |
6,020
-13,678
| -69% | -$501K |
|
2019
TOP Ships
TOPS
$4.32M
| $221K | ﹤0.01% |
+851
| New | +$379K |
|
|
UCTT
2020
Ultra Clean Holdings
UCTT
$4.16B
| $221K | ﹤0.01% |
10,320
-17,043
| -62% | -$414K |
|
|
SAFE
2021
DELISTED
Safehold Inc.
SAFE
| $221K | ﹤0.01% |
+3,560
| New | +$193K |
|
2022
First Merchants
FRME
$2.72B
| $220K | ﹤0.01% |
+9,499
| New | +$237K |
|
2023
Global Net Lease
GNL
$1.87B
| $220K | ﹤0.01% |
+13,858
| New | +$234K |
|
2024
Red River Bancshares
RRBI
$655M
| $220K | ﹤0.01% |
+5,127
| New | +$221K |
|
2025
CALL
ExxonMobil
XOM
$651B
| $220K | ﹤0.01% |
6,400
+200
| +3% | +$8.18K |
|
Similar funds
Squarepoint's Q3 2020 Portfolio in Review
As of Q3 2020, Squarepoint held 3,037 positions worth $7.42B, up 20% from $6.18B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Squarepoint deployed $985M of net new capital in Q3 2020, opening 854 new positions and adding to 791 existing holdings. Its largest new stake was Salesforce: 186,017 shares worth $46.8M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Pfizer, an estimated $41M trimmed.
- Squarepoint's largest Q3 2020 buy was Salesforce: 186,017 shares worth $46.8M.
- Squarepoint added most to Visa in Q3 2020, an estimated $49.3M increase.
- Squarepoint's biggest Q3 2020 reduction was Pfizer, cutting an estimated $41M.
- Squarepoint fully exited Biogen in Q3 2020, selling an estimated $36.8M.
- Squarepoint's ten largest holdings make up 11% of its $7.42B portfolio in Q3 2020.
- Squarepoint opened 854 new positions and closed 600 in Q3 2020.
- Squarepoint's portfolio value rose 20% quarter-over-quarter to $7.42B.
Based on Squarepoint's 13F filing for Q3 2020, filed 16 Nov 2020.